Top

International Journal of Clinical Oncology

Published in:

01-06-2014 | Original Article

Influence of body mass index on clinicopathological factors including estrogen receptor, progesterone receptor, and Ki67 expression levels in breast cancers

Authors: Ayako Yanai, Yoshimasa Miyagawa, Keiko Murase, Michiko Imamura, Tomoko Yagi, Shigetoshi Ichii, Yuichi Takatsuka, Takashi Ito, Seiichi Hirota, Mitsunori Sasa, Toyomasa Katagiri, Yasuo Miyoshi

Published in: International Journal of Clinical Oncology | Issue 3/2014

Abstract

Background

High body mass index (BMI) is associated not only with a higher incidence of breast cancers but also with poorer prognosis. It is speculated that both enhanced production of estrogens and other factors associated with obesity are involved in these associations, but the biological characteristics associated with high BMI have yet to be thoroughly identified.

Methods

We studied 525 breast cancers, focusing on biological differences between tumors associated with high and low BMI and by immunohistochemically defined intrinsic subtype. Ki67 expression levels were used to differentiate luminal A from luminal B estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)-breast cancers.

Results

Premenopausal patients with high BMI showed a significantly higher frequency of lymph node metastasis (46.4 % vs. 22.9 %, P = 0.005) and tended to have a larger tumor size (P = 0.05) and higher nuclear grade (P = 0.07) than those with low BMI. These differences were not observed among postmenopausal patients. BMI was not associated with distribution of breast cancer subtypes, and ER, progesterone receptor (PR), and Ki67 expression levels of each subtype showed no differences between high and low BMI among premenopausal patients.

Conclusion

Higher BMI might influence aggressive tumor characteristics among premenopausal patients, but its influence on ER, PR, and Ki67 expression levels seems to be limited.

Renehan AG, Tyson M, Egger M et al (2008) Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 371(9612):569–578PubMedCrossRef

Harvie M, Hooper L, Howell AH (2003) Central obesity and breast cancer risk: a systematic review. Obes Rev 4(3):157–173PubMedCrossRef

McTiernan A, Rajan KB, Tworoger SS et al (2003) Adiposity and sex hormones in postmenopausal breast cancer survivors. J Clin Oncol 21(10):1961–1966PubMedCentralPubMedCrossRef

Phipps AI, Malone KE, Porter PL et al (2008) Body size and risk of luminal, HER2-overexpressing, and triple-negative breast cancer in postmenopausal women. Cancer Epidemiol Biomarkers Prev 17(8):2078–2086PubMedCentralPubMedCrossRef

Berclaz G, Li S, Price KN et al (2004) Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience. Ann Oncol 15(6):875–884PubMedCrossRef

Kawai M, Minami Y, Nishino Y et al (2012) Body mass index and survival after breast cancer diagnosis in Japanese women. BMC Cancer 12:149PubMedCentralPubMedCrossRef

Sparano JA, Wang M, Zhao F et al (2012) Obesity at diagnosis is associated with inferior outcomes in hormone receptor-positive operable breast cancer. Cancer (Phila) 118(23):5937–5946CrossRef

Dawood S, Lei X, Litton JK et al (2012) Impact of body mass index on survival outcome among women with early stage triple-negative breast cancer. Clin Breast Cancer 12(5):364–372PubMedCrossRef

Sestak I, Distler W, Forbes JF et al (2010) Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial. J Clin Oncol 28(21):3411–3415PubMedCrossRef

10.

Cheang MC, Chia SK, Voduc D et al (2009) Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 101(10):736–750PubMedCentralPubMedCrossRef

11.

Biglia N, Peano E, Sgandurra P et al. (2013) Body mass index (BMI) and breast cancer: impact on tumor histopathologic features, cancer subtypes and recurrence rate in pre and postmenopausal women. Gynecol Endocrinol 29(3):263–267

12.

Daling JR, Malone KE, Doody DR et al (2001) Relation of body mass index to tumor markers and survival among young women with invasive ductal breast carcinoma. Cancer (Phila) 92(4):720–729CrossRef

13.

Goodwin PJ, Ennis M, Pritchard KI et al (2002) Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J Clin Oncol 20(1):42–51PubMedCrossRef

14.

Goodwin PJ, Ennis M, Bahl M et al (2009) High insulin levels in newly diagnosed breast cancer patients reflect underlying insulin resistance and are associated with components of the insulin resistance syndrome. Breast Cancer Res Treat 114(3):517–525PubMedCrossRef

15.

Irwin ML, Duggan C, Wang CY et al (2011) Fasting C-peptide levels and death resulting from all causes and breast cancer: the health, eating, activity, and lifestyle study. J Clin Oncol 29(1):47–53PubMedCentralPubMedCrossRef

16.

Viale G, Regan MM, Maiorano E et al (2008) Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors. International Breast Cancer Study Group. J Clin Oncol 26(9):1404–1410PubMedCrossRef

Title: Influence of body mass index on clinicopathological factors including estrogen receptor, progesterone receptor, and Ki67 expression levels in breast cancers
Authors: Ayako Yanai
Yoshimasa Miyagawa
Keiko Murase
Michiko Imamura
Tomoko Yagi
Shigetoshi Ichii
Yuichi Takatsuka
Takashi Ito
Seiichi Hirota
Mitsunori Sasa
Toyomasa Katagiri
Yasuo Miyoshi
Publication date: 01-06-2014
Publisher: Springer Japan
Published in: International Journal of Clinical Oncology / Issue 3/2014
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-013-0585-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2014

Current status of oral cancer treatment strategies: surgical treatments for oral squamous cell carcinoma

Oral cancer: current status of molecular biology and treatment strategy

Intraoperative diagnosis of lymph node metastasis by transcription–reverse transcription concerted reaction assay in gastric cancer

Orally administered S-1 suppresses circulating endothelial cell counts in metastatic breast cancer patients

Surveillance biopsy and active treatment during active surveillance for low-risk prostate cancer

NRAS mutations in primary and metastatic melanomas of Japanese patients

Keynote webinar | Spotlight on antibody–drug conjugates in cancer